ICE Bioscience Inc., established in 2010 in Beijing, focuses on an integrated biological services platform for innovative drug discovery, encompassing target identification and validation, lead compound screening, optimization, and pre-clinical candidate stages. It pioneers an innovative CRO+ model in biological and pharmacological research technologies across oncology, immunology, cardiovascular, central nervous system, and metabolism diseases.
ICE Bioscience expert electrophysiology team has led the way in early drug discovery since 2010, specializing in ion channel screening and cardiac safety assessment. Our reputation is built on comprehensive services from target validation to preclinical candidate identification.
Two prominent modalities within targeted protein degradation are PROTACs (Proteolysis Targeting Chimeras) and molecular glues. PROTACs function by recruiting an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. This strategy enables the degradation of proteins considered "undruggable" by traditional small molecule inhibitors. On the other hand, molecular glues induce protein-protein interactions that result in the degradation of specific targets, providing an alternative approach to PROTACs.
ICE Bioscience Protein Science Platform offers integrated custom protein services, including cloning, expression, purification, quality control, and activity determination. The platform boasts over 1200 enzymatic assays, 700 target protein products, and more than 50 validated SPR assays, supporting new drug development for global partners.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
